Feb 4, 2025 · In summary, a KP.2 MV booster elicits robust short-term neutralising antibodies against the recent SARS-CoV-2 subvariants KP.3.1.1 and XEC. The durability of this booster response needs to be assessed in time, as well as the associated clinical efficacy.

So, COVID-19 vaccines available in the U.S. this fall will differ as to which variant will be used. The protein-based vaccine, made by Novavax, will use JN1, and the mRNA-based vaccines, made by both Pfizer and Moderna, will use KP2. What does this mean for people getting vaccinated this fall?

Jun 20, 2024 · Less than a week after telling COVID-19 vaccine manufacturers to target the JN.1 variant this fall, the Food and Drug Administration (FDA) reversed course. The FDA is now asking vaccine manufacturers Pfizer, Moderna, and Novavax to target an offshoot of JN.1, called KP.2, instead—“if feasible.”

One new variant, KP.2, could lead the surge during the upcoming summer. This recently identified variant is mainly spreading in the United States, Canada, and the United Kingdom, with rising levels in Singapore, New Zealand, and Australia.

May 31, 2024 · One new variant, KP.2, could lead the surge during the upcoming summer. This recently identified variant is mainly spreading in the United States, Canada, and the United Kingdom, with rising...

Aug 22, 2024 · The KP.2 adaptation is based on guidance from the FDA, which stated that KP.2 is the preferred strain of the JN.1 lineage for COVID-19 vaccines for use in the U.S. during the 2024-2025 fall and winter season, if feasible. 1 Staying up to date on vaccinations in line with the Centers for Disease Control and Prevention (“CDC”) recommendations rema...

Aug 22, 2024 · KP.2 was the dominant Covid strain in May, but now only accounts for roughly 3% of all U.S. cases as of Saturday, according to the latest Centers for Disease Control and Prevention data.

May 20, 2024 · Here, we investigated the virological properties of KP.2. KP.2 has three substitutions in the S protein including the two above and an additional substitution in the non-S protein compared with JN.1 (appendix p 15).

Aug 30, 2024 · Vaccine providers approved to provide shots for younger children should know that unvaccinated infants and toddlers aged 6 months through 4 years are eligible to receive three doses of the updated, authorized Pfizer-BioNTech COVID-19 vaccine or two doses of the updated, authorized Moderna COVID-19 vaccine.

Apr 26, 2024 · Particularly, the KP.2 (JN.1.11.1.2) variant, a descendant of JN.1 bearing both S:R346T and S:F456L, is rapidly spreading in multiple regions as of April 2024. Here, we investigated the virological properties of KP.2.